VEGF inhibition and renal thrombotic microangiopathy - Wikidata - wikimedia - TriplyDB

VEGF inhibition and renal thrombotic microangiopathy

VEGF inhibition and renal thrombotic microangiopathy

http://www.wikidata.org/entity/Q24632792

about

Atypical hemolytic uremic syndrome Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Angiopoietin-1 is essential in mouse vasculature during development and in response to injury.Thrombotic microangiopathy with targeted cancer agents Shiga toxin 2 targets the murine renal collecting duct epithelium Cancer-associated thrombotic microangiopathy Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Bevacizumab for glioblastoma Thrombotic microangiopathy associated with proteasome inhibitors Angiogenic factors in preeclampsia: potential for diagnosis and treatment Cell biology and pathology of podocytes A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury Medical management of brain tumors and the sequelae of treatment.Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Molecular mechanisms of diabetic kidney disease Practical management of bevacizumab-related toxicities in glioblastoma On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review HUS and TTP in Children Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy Epidermal growth factor: a new therapeutic target in glomerular disease.Drug-induced glomerular disease: direct cellular injury.Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients Hemolytic uremic syndrome: toxins, vessels, and inflammation Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia Crosstalk in glomerular injury and repair Update on the glomerular filtration barrier WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier Targeted deletion of Vegfa in adult mice induces vision loss A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.Chronic VEGF blockade worsens glomerular injury in the remnant kidney model Nck proteins maintain the adult glomerular filtration barrier.Antineoplastic agents and thrombotic microangiopathy.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Angiogenic inhibition in high-grade gliomas: past, present and future.Overexpression of VEGF165b in podocytes reduces glomerular permeability.Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.

P2860

Q21202864-4E22DE9B-6806-46D0-A5E0-009198390165 Q24337607-2FD44C46-B249-4B51-8359-331E57E99C0E Q24629743-6D15DBE4-4C3A-4867-AB3C-6F83DD9BBB0D Q24635904-56B573C0-73F2-4273-9523-04AD8C40F43B Q24652310-63901976-D89F-497F-82CE-319D5138DFDB Q26738984-499A72EF-AC72-42AB-B9FB-6B7FD4BA6219 Q26751280-BC85790B-2F08-4126-BA15-9F24D68B20B6 Q26776307-3C39579C-E431-4ADE-960D-3E400C0B044C Q26785826-68801B66-2F40-425E-9B7E-C6B13480C921 Q26825774-6EB96D4C-5E06-4561-8D21-1A293115BF18 Q26853664-A9E60301-F7AB-4A67-A0EF-FF63C17C3AA8 Q26992169-F7BF35D7-44D8-43CB-9CBA-B844768BF307 Q26992174-367D91D7-1878-4506-BCDA-D2012034A0DF Q27002538-B907E2F6-ED68-4323-9C45-ECAD57F8B058 Q27003963-1A409695-438E-4336-A48A-6A39C641D473 Q27015852-80576AC3-5DA0-4EDC-A95F-D205CEB7E991 Q27025624-22E96D7E-63AD-44F7-96D9-FAF4708D13F4 Q27026538-D0CA1311-DAAB-4819-8E5B-9260B6879C76 Q27342809-AE1095BC-115E-422C-8B8E-7E37FA1CF729 Q27686898-621647DF-99A7-4A8A-829F-F4FDFC6345C4 Q27692666-6192BED6-C6EF-41DF-81F2-9E2EEBB34660 Q28066747-01B337B9-0EAC-41D5-B572-E21742FAFFC9 Q28074157-447EFDDB-E4E7-4027-B4E4-859F2765F255 Q28080163-260ADE33-5A39-4ED7-B2D3-9DB927989DBA Q28083347-97127EEC-F147-44A3-9307-CD1EEECE42A2 Q28083815-DA8892E0-629C-4295-968F-08BD756FBA3C Q28085092-922655CF-0E14-4FAE-AD02-9CC174C870DA Q28241692-F4EDD643-8C53-4E7E-A1A5-71E247466A21 Q28506573-4DADDDDC-C2AB-49BF-B6D3-5B37A4ECF282 Q28513588-F1DF26F1-E91E-4E8C-B9D9-9332D8E7D21C Q28566820-C375A843-5E4C-4C25-9657-5ECD8BF5A3D2 Q28728129-D6DFBCEF-A164-478F-B85E-32ECE8013561 Q30157251-CBE04AD7-3157-4112-B181-51381CC6CC19 Q30251919-079A6A01-993C-4FBD-89B2-5A3281E32637 Q30276550-E023731D-4745-4B86-8040-F69665D58F76 Q30417015-984F998B-F44D-4D08-A68F-1BB7CC3EF247 Q30455596-241573AD-E15F-40A6-87DB-F02E0C4519DC Q30497786-15174C65-9BA5-49A8-94F5-ADA5A77DC0EF Q30500731-F70C9D4F-B776-403F-817C-20F6CBC34293 Q30616602-64D9837A-05FC-4DEA-BCE0-9BB296910A09

P2860

VEGF inhibition and renal thrombotic microangiopathy

http://www.wikidata.org/entity/Q24632792

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

VEGF inhibition and renal thrombotic microangiopathy

@ast

VEGF inhibition and renal thrombotic microangiopathy

@en

VEGF inhibition and renal thrombotic microangiopathy

@nl

type

label

VEGF inhibition and renal thrombotic microangiopathy

@ast

VEGF inhibition and renal thrombotic microangiopathy

@en

VEGF inhibition and renal thrombotic microangiopathy

@nl

prefLabel

VEGF inhibition and renal thrombotic microangiopathy

@ast

VEGF inhibition and renal thrombotic microangiopathy

@en

VEGF inhibition and renal thrombotic microangiopathy

@nl

P1433

Q24632792-499BB32B-2FAC-482B-A145-74EF75378FAE

P1476

Q24632792-97211508-4813-4749-8508-34E5822FE9D0

P2093

Q24632792-0FDD975C-C7B1-4780-A64E-2330E337D643

Q24632792-29B8EA2D-9EF9-4AE3-99EC-06ED0ED0F60F

Q24632792-34C2069A-C46F-49F8-A58A-92739F996BC6

Q24632792-4360952A-AB5D-4F49-A5B6-833265B6EE78

Q24632792-683ED414-AB9D-460B-9123-7A878515627C

Q24632792-7320A8F9-63F8-430F-8F4E-A0794CADCF70

Q24632792-7398E31B-9171-4EEC-93DD-73D6C5FE8AF9

Q24632792-8EC3853A-F9C3-47A5-B216-0E6814EA85C0

Q24632792-970D686B-78B2-469C-A82F-16D893B42D77

Q24632792-97DDA27B-3E07-404E-A3A4-C6BDDE2A739C

P2860

Q24632792-0BFCEB54-1A7A-49C6-8713-FEEEB8F2BCC3

Q24632792-1E951FDF-E5D7-457E-B662-C7F5645AC1EB

Q24632792-3EFD36BE-08DF-4925-B996-1E46D70B1417

Q24632792-4F9C5FD8-F418-4BEA-B28E-EDF028DD8BE7

Q24632792-551841FA-69F8-4342-B55A-3ED99E45F755

Q24632792-64F7EE87-5415-4E2B-A28C-70A237318B32

Q24632792-807B4A6B-40C4-48CB-B87B-EFF5BA878299

Q24632792-924B01DC-5F44-4BF9-83A2-45546B4EF0AB

Q24632792-AF1B2697-4EAE-49AC-B729-BE42EEDD277C

Q24632792-B353E212-5E35-419E-AEF9-01EC22F796B4

P304

Q24632792-40D23B26-B021-4290-8529-C84BF213FDA8

P31

Q24632792-C31F9432-E646-44CB-B67B-9271194C908C

P3181

Q24632792-E0BEA90F-9615-4CB3-BE50-2F20DDB2CF47

P356

Q24632792-2778B149-D221-47D6-A8A2-11CA2CD23760

P407

Q24632792-0D4608F1-5FAF-4B2F-995D-B16D37E2DDC0

P433

Q24632792-12958F1E-99D0-4BAC-B329-D6AA431814CA

P478

Q24632792-6659EDBD-39D3-41C9-B2C0-3C24CA22A998

P50

Q24632792-534216E4-38B2-4C3F-93D8-9503E1C6D67C

Q24632792-B10ACD3A-2357-4BA1-AA13-F99390FD7441

P577

Q24632792-93324622-AFB7-4F63-8B94-29A58AD975EC

P698

Q24632792-F56E051E-DE60-48F0-A7DD-2FA72E33BE6A

P932

Q24632792-97C483ED-EFF0-4888-A4E2-77059386C87A

P3181

P356

P1433

The New England Journal of Medicine

P1476

VEGF inhibition and renal thrombotic microangiopathy

@en

P2093

Catherine Richardson

http://www.w3.org/2001/XMLSchema#string

Charles E Alpers

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Gerber

http://www.w3.org/2001/XMLSchema#string

Howard Hochster

http://www.w3.org/2001/XMLSchema#string

J Ashley Jefferson

http://www.w3.org/2001/XMLSchema#string

Jolanta Kowalewska

http://www.w3.org/2001/XMLSchema#string

Joseph Weisstuch

http://www.w3.org/2001/XMLSchema#string

Laura Barisoni

http://www.w3.org/2001/XMLSchema#string

M Golam Kabir

http://www.w3.org/2001/XMLSchema#string

Mark Haas

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF(165) mediates glomerular endothelial repair

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

Glomerular endothelial cell differentiation.

Nephrotic syndrome after bevacizumab: case report and literature review.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Vascular endothelial growth factor trap in non small cell lung cancer.

Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules.

P304

1129-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

461680

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0707330

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P50

Napoleone Ferrara

Jeffrey B. Kopp

P577

2008-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18337603

http://www.w3.org/2001/XMLSchema#string

P932

3030578

http://www.w3.org/2001/XMLSchema#string